Search
01/01/2023
Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast
John T., Majem M., Legg D., Goldman J.. Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast. Targeted Oncology. 2023; 18(1)DOI:10.1007/s11523-022-00927-5. PMID:36534268. IF:4.400(Q2/3D).
01/01/2023
Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review
Blakely C.M., Weder W., Bubendorf L., He J., Majem M., Shyr Y., Chaft J.E.. Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer: A review. LUNG CANCER. 2023; 177DOI:10.1016/j.lungcan.2023.01.002. PMID:36736076. IF:4.500(Q1/2D).
01/01/2023
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Vidal J., Fernández-Rodríguez M.C., Casadevall D., García-Alfonso P., Páez D., Guix M., Alonso V., Cano M.T., Santos C., Durán G., Elez E., Manzano J.L., Garcia-Carbonero R., Ferreiro R., Losa F., Pineda E., Sastre J., Rivera F., Bellosillo B., Tabernero J., Aranda E., Salazar R., Montagut C.. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study. CLINICAL CANCER RESEARCH. 2023; 29(2)DOI:10.1158/1078-0432.CCR-22-1696. PMID:36074154. IF:10.400(Q1/1D).
01/01/2023
Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section
Martinez D.A.S., Quilez-Cutillas A., Jimenez-Labaig P., Sesma A., Tarazona N., Pacheco-Barcia V., Obispo B., Paez D., Quintanar T., Sanchez-Canovas M., Montes A.F., Felip E., Rodriguez-Lescure A., Elez E.. Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02989-3. PMID:36418642. IF:2.800(Q2/5D).
01/01/2023
Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (Nature Communications, (2023), 14, 1, (1070), 10.1038/s41467-023-35961-y)
Chmielecki J., Gray J.E., Cheng Y., Ohe Y., Imamura F., Cho B.C., Lin M.-C., Majem M., Shah R., Rukazenkov Y., Todd A., Markovets A., Barrett J.C., Hartmaier R.J., Ramalingam S.S.. Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (Nature Communications, (2023), 14, 1, (1070), 10.1038/s41467-023-35961-y). Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-38999-0. PMID:37263992. IF:14.700(Q1/1D).
01/01/2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors
Bertran-Alamillo J., Giménez-Capitán A., Román R., Talbot S., Whiteley R., Floc’h N., Martínez-Pérez E., Martin M.J., Smith P.D., Sullivan I., Terp M.G., Saeh J., Marino-Buslje C., Fabbri G., Guo G., Xu M., Tornador C., Aguilar-Hernández A., Reguart N., Ditzel H.J., Martínez-Bueno A., Nabau-Moretó N., Gascó A., Rosell R., Pease J.E., Polanska U.M., Travers J., Urosevic J., Molina-Vila M.A.. BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors. Molecular Cancer. 2023; 22(1)DOI:10.1186/s12943-023-01815-w. PMID:37443114. IF:27.700(Q1/1D).